

June 2003

Issue 12

Headlines:

- 2nd ENOS Investigator meeting
- SARS halts recruitment in Singapore
- Important change to 'Patch SOP'
- New centres for ENOS

ENOS milestones:

- 1st patient – 20/7/01
- 2nd site – 26/12/01
- Largest GTN trial (n=91) – 17/3/03
- Bigger than metanalysis (n=128) – 8/6/03

Recruitment total: 131

- Aberdeen - 15
- Bishop Auckland - 9
- Boston - 0
- Cheltenham - 0
- Halifax (Canada) - 3
- Liverpool - 1
- Mansfield - 0
- Manila - 0
- Nottingham (City) - 50
- Nottingham (QMC) - 0
- Sheffield (Hallamshire) - 1
- Singapore - 34
- Sydney (Canada) - 0
- Rhyl - 0
- Warsaw (IPN) - 14
- Warsaw (MMA) - 4

ENOS NEWS

The Newsletter for the Efficacy of Nitric Oxide in Stroke Trial

2nd ENOS Investigator's Meeting, Valencia

The ENOS trial recently held its 2nd Investigator Meeting at the European Stroke Conference in Valencia, Spain. The meeting, which was run in conjunction with several UK trials, gave ENOS investigators an opportunity to discuss trial related issues with investigators who participate in other studies. We'd like to thank all those who attended and helped

make the meeting a success.

In addition to this, new data that is relevant to ENOS was presented at the European Stroke Conference. In a systematic review of the effect of administration of nitric oxide donors and substrate to models of transient and permanent ischaemia, there was evidence of reduced infarct

volume and increased cerebral blood flow.

¹. Systematic review of NO donors and L-Arginine in experimental stroke: Effects on infarct size and cerebral blood flow (abstract). Cerebrovasc Dis 2003;16(suppl 4):66-67

SARS epidemic halts recruitment in Singapore

Recruitment in Singapore was recently halted during the peak of the SARS epidemic.

Fortunately, SARS is on the wane and Singapore should be recruiting again in the near future.

Important change to patch 'Standard Operating Procedure'

We would like to draw your attention to a recent change in one of the standard operating procedures (SOPs) used in the ENOS trial. Investigators are now requested to cover GTN patches with a dressing (or alternatively simply

place a dressing on control patients) in order to make ENOS single blind in design. Obviously it will not be possible to blind people to whether they have had their prior antihypertensive medication stopped or continued. Current ENOS investigators will have

received an updated version of the ENOS patch application SOP which covers this change.

2 New Centres for ENOS

Congratulations to our two new international centres in Sydney (Canada) and Manila (Philippines). We would like to welcome them to the ENOS trial and we wish them well in recruiting

their first patients shortly. As always, we welcome other interested sites to fax, email or post the form that is attached with this newsletter to the ENOS trial office. You will find the

address for this below. Also, please note that if you don't have time to fill out a lengthy ethics application then we can often help with this.

ENOS Trial Office, Division of Stroke Medicine, University of Nottingham, City Hospital Campus, Nottingham NG5 1PB.

Tel or Fax. 0115 840 4795. Email : enos@nottingham.ac.uk, Website www.nottingham.ac.uk/stroke-medicine/enosindex.htm Principal investigator: Philip Bath. Trial Manager: Chris Weaver. Trial Medic: Mark Willmot.

Expression of interest in ENOS

Many thanks for your interest in ENOS. We are trying to recruit as many sites as possible and it would help if you could provide us with some information about your facilities. This form should be faxed or posted to the ENOS trial co-ordinating centre in Nottingham.

Name <div style="border: 1px solid black; height: 20px; width: 100%;"></div>	Postal Address <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
Email <div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
Telephone Number <div style="border: 1px solid black; height: 20px; width: 100%;"></div>	Fax Number <div style="border: 1px solid black; height: 20px; width: 100%;"></div>

Approximately how many strokes are admitted to your hospital each year?	
How many patients per month do you estimate you could recruit for ENOS?	
When might you be able to start recruiting?	<div style="border: 1px solid black; height: 20px; width: 100%;"></div>

Do you already have any of the following (those marked with * are essential to participate in ENOS):

An acute stroke unit / area?	Yes / No	(If yes, how many beds?.....)
A stroke rehabilitation unit / area?	Yes / No	(If yes, how many beds?.....)
A research nurse?	Yes / No	
A research doctor?	Yes / No	
A stroke / TIA outpatients clinic?	Yes / No	
Internet access?*	Yes / No	
Internet access on a stroke ward?	Yes / No	
Access to a fax machine?*	Yes / No	

Access to laboratory facilities for centrifuging and storage of frozen serum and EDTA blood samples?
Yes / No

Can patients have a CT or MRI head scan by 7 days from the time of randomisation?*

Yes / No

Have you been involved in any academic or commercial stroke trials in the last 10 years? Please give examples below.

ENOS Trial Office, Division of Stroke Medicine, University of Nottingham, City
Hospital Campus, Nottingham NG5 1PB.

Tel or Fax. 0115 840 4795. Email : enos@nottingham.ac.uk, Website www.nottingham.ac.uk/stroke-medicine/enosindex.htm Principal investigator: Philip Bath. Trial Manager: Chris Weaver. Trial Medic: Mark Willmot.